Document Detail


International multicentre study examining selection criteria for active surveillance in men undergoing radical prostatectomy.
MedLine Citation:
PMID:  23037714     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: The controversies concerning possible overtreatment of prostate cancer, highlighted by debate over PSA screening, have highlighted active surveillance (AS) as an alternative management option for appropriate men. Regional differences in the underlying prevalence of PSA testing may alter the pre-test probability for high-risk disease, which can potentially interfere with the performance of selection criteria for AS. In a multicentre study from three different countries, we examine men who were initially suitable for AS according to the Toronto and Prostate Cancer Research International: Active Surveillance (PRIAS) criteria, that underwent radical prostatectomy (RP) in regards to:1.the proportion of pathological reclassification(Gleason score ≥7, ≥pT3 disease),2.predictors of high-risk disease,3.create a predictive model to assist with selection of men suitable for AS.
METHODS: From three centres in the United Kingdom, Canada and Australia, data on men who underwent RP were retrospectively reviewed (n=2329). Multivariable logistic regression was performed to identify predictors of high-risk disease. A nomogram was generated by logistic regression analysis, and performance characterised by receiver operating characteristic curves.
RESULTS: For men suitable for AS according to the Toronto (n=800) and PRIAS (410) criteria, the rates for upgrading were 50.6, 42.7%, and upstaging 17.6, 12.4%, respectively. Significant predictors of high-risk disease were:•Toronto criteria: increasing age, cT2 disease, centre of diagnosis and number of positive cores.•PRIAS criteria: increasing PSA and cT2 disease.Cambridge had a high pT3a rate (26 vs 12%). To assist selection of men in the United Kingdom for AS, from the Cambridge data, we generated a nomogram predicting high-risk features in patients who meet the Toronto criteria (AUC of 0.72).
CONCLUSION: The proportion of pathological reclassification in our cohort was higher than previously reported. Care must be used when applying the AS criteria generated from one population to another. With more stringent selection criteria, there is less reclassification but also fewer men who may benefit from AS.
Authors:
L-M Wong; D E Neal; R B Johnston; N Shah; N Sharma; A Y Warren; C M Hovens; S Larry Goldenberg; M E Gleave; A J Costello; N M Corcoran
Related Documents :
22963784 - Travel trends and patterns of travel-associated morbidity.
8808044 - Epidemiologic assessment of laboratory animal allergy among university employees.
23628224 - Development and validation of a necrotizing soft-tissue infection mortality risk calcul...
22958664 - Contraceptive features preferred by women at high risk of unintended pregnancy.
10614714 - Moderate alcohol consumption: the gentle face of janus.
1752934 - Evaluation of the risk of pelvic infection following transvaginal oocyte recovery.
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial     Date:  2012-10-04
Journal Detail:
Title:  British journal of cancer     Volume:  107     ISSN:  1532-1827     ISO Abbreviation:  Br. J. Cancer     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-24     Completed Date:  2013-03-21     Revised Date:  2013-04-16    
Medline Journal Info:
Nlm Unique ID:  0370635     Medline TA:  Br J Cancer     Country:  England    
Other Details:
Languages:  eng     Pagination:  1467-73     Citation Subset:  IM    
Affiliation:
Department of Urology, Addenbrooke's Hospital, Cambridge, UK. lihmingwong@gmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Early Detection of Cancer / methods
Humans
Male
Middle Aged
Nomograms
Prospective Studies
Prostate-Specific Antigen / analysis
Prostatectomy / methods*
Prostatic Neoplasms / diagnosis*,  pathology,  surgery*
Retrospective Studies
Risk Factors
Chemical
Reg. No./Substance:
EC 3.4.21.77/Prostate-Specific Antigen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The FOXM1-PLK1 axis is commonly upregulated in oesophageal adenocarcinoma.
Next Document:  Ligand-independent activation of EphA2 by arachidonic acid induces metastasis-like behaviour in pros...